Four Champaign Co. restaurants receive yellow alerts in health inspections
CHAMPAIGN COUNTY, Ill. (WCIA) — In the latest round of health inspections, four Champaign County restaurants received less than satisfactory results.
On March 27, Tenkyu, located at 301 N Neil St. in Champaign, received a yellow food safety alert after a routine health inspection. The inspector found seven risk factor/intervention violations, two of which were repeated violations.
Federal government tariffs may increase car prices
This included a container of raw squid that was stored above several containers of ready-to-eat sauces in the make table reach-in coolers near the fryers. Another violation was three containers of raw beef and two containers of raw chicken that were stored above containers of cooked rice, cooked chicken, sauce, soup and containers of tofu in the walk-in cooler.
This is the third consecutive inspection that cross-contamination violations have been documented, which resulted in a yellow food safety alert being posted.
Another violation that was repeated for a third time was a consumer advisory-disclosure and reminder violation. In this inspection, an asterisk was not provided for the tuna in the 'Tenkyu Roll,' for the tuna in the 'In N Out Roll,' for the tuna, salmon and flying fish roe in the 'Tuna sandwich,' or for the specific animal derived foods in the 'Sushi' section of the menu.
Other notable violations include a container of cigarettes that was stored next to clean utensils and several packages of raw beef and quail that were 50°F to 54°F and not submerged under cold running water or kept below 41°F during the thawing process. A follow-up inspection will take place in 5-7 business days from that date to ensure corrections have been made.
ET's Downtown Rantoul, located at 107 E Sangamon Ave. in Rantoul, received a yellow food safety alert on March 28. A health inspector found a total of six risk factor/intervention violations, two of which were repeated violations.
Tolono could have first African American Village President
A cold holding 41°F or less violation was found for the fourth consecutive time during a routine checkup, resulting in a yellow food safety alert being posted and a compliance meeting being scheduled. During the latest inspection, the following were above 41°F in the top portion of the make table cooler:
Three containers of cut lettuce (45.3°F, 53.2°F, 51.1°F)
One container of pico de gallo (46.9°F)
Two containers of cut tomatoes (45.5°F and 48°F)
One container of shredded cheese (45°F to 48°F)
One container of coleslaw (46.8°F)
One container of cut spinach (52.9°F)
There were six separate violations found under this category alone, including a number of foods that were over the necessary cooling temperatures.
The other repeat violation that was found was a cooling-cooked time/temperature control for safety foods violation, which was observed for the second consecutive routine inspection. In this inspection, cooked chicken wings (prepared the day before) were 44.1°F in the walk-in cooler. According to an employee, the chicken wings had remained in the cooler since the previous day.
The compliance meeting was scheduled for April 2 at 10:30 a.m. A number of discussion notes were also posted at the bottom of the report.
On March 31, H Mart, located at 220 N Broadway Ave in Urbana, received a yellow food safety alert. While no risk factor/intervention violations were found in the inspection, a violation correction form (VCF) was not completed by its due date.
Champaign Police increasing patrol to combat distracted drivers
This form was issued during the routine inspection on Feb. 28 in response to a food package labeling violation for several facility-packaged food items that were not labeled with the major allergens they contained. Adequate food labels for the facility-packaged foods were not received by the VCF extended due date of March 28 at 4 p.m.
As a result, a yellow food safety alert was posted. In addition, if adequate food labels for facility-packaged foods are not received by 4 p.m. on April 11, the health permit will be suspended, and H Mart will receive a red 'Closed' placard.
Urbana Country Club, located at 100 E Country Club Road in Urbana, received a yellow food safety alert on April 1. Four risk factor/intervention violations were found, one of which was a repeat violation during the inspection.
A cold holding 41°F or less violation was found during the third consecutive routine inspection, which resulted in the yellow food safety alert being issued. In this particular inspection, the following items were found inside in the 'Turbo-air' make-table cooler on the left side of the pizza oven: Hard-boiled eggs (48.2°F) inside the top part, chicken salad (46.2°F) and cut melons (44.6°F) inside the reach-in part.
Police respond to car versus bicyclist accident in Champaign
Additionally, the following items were found inside the pull-out coolers opposite the grill on the cookline:
Chili (46°F)
Pulled short ribs (62.4°F)
Corned beef (48.5°F)
Diced ham (46.2°F)
Cooked pasta (43.8°F)
Mushroom cream sauce (46.7°F)
Shredded cheddar cheese (46.5°F)
An employee said that the chili was thawed under cold running water for 45 minutes and was added to the pull-out cooler approximately 2.5 hours before, the short rib was pulled, portioned and added to the pull-out cooler approximately 2.5 hours prior, corned beef was portioned and added to the pull-out cooler approximately 3 hours prior, ham, pasta and mushroom cream sauce were moved from the walk-in cooler to the pull-out cooler approximately 4 hours prior and the cheese was sitting in the cooler since the week before.
As a result of the repeated violation, a Repeat P & Pf Root Cause Questionnaire was scheduled for April 2 at 9 a.m. and a follow-up inspection will be conducted to verify the long-term violation correction in 5-7 business days after the questionnaire is completed. Adequate checklists for the cold holding violation must be sent to the Champaign County Health Department by 8 a.m. on April 8.
For more information on other recent restaurant inspections, visit the Champaign-Urbana Public Health District's website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteers Management to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 5 posters presented at the EHA 2025 annual meeting in Milan, Italy. This year's presentations included data from HELIOS, an ongoing open-label extension study of bitopertin in EPP, which showed favorable long-term efficacy and safety with sustained protoporphyrin IX (PPIX) reductions, improvement in quality of life, and improved liver biomarkers. Disc is advancing development and registrational activities for bitopertin in EPP, with plans to submit an NDA in H2 2025. The company has initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP. Disc recently launched a campaign to raise awareness of EPP among physicians, patients, and caregivers with emphasis on the causative role of PPIX accumulation in the disease. Learn more at Disc also presented longer term data from the continuation phase of its Phase 1b trial in MF anemia, showing sustained activity on key biomarkers and durable anemia response among major responders. Enrollment for the Phase 2 RALLY-MF trial of DISC-0974 is ongoing with the exploratory cohort for patients on concomitant momelotinib or pacritinib fully enrolled. The company expects to present initial RALLY-MF data in H2 2025. Additionally, Disc shared an update of the Phase 1 healthy volunteer trial of DISC-3405, initially presented at ASH 2024, which demonstrated deep, sustained reductions in serum iron and meaningful changes in hematologic parameters, establishing proof of mechanism. Based on these data, the company has initiated a Phase 2 trial of DISC-3405 in polycythemia vera (PV). Disc also presented an iron pulse study of DISC-3405 in healthy volunteers which showed inhibition of dietary iron uptake, further confirming the mechanism of action and supporting DISC-3405's potential in diseases of iron overload. The collection of data presented at EHA adds to the evidence base supporting Disc's continued advancement of all three clinical candidates and provides support for expansion opportunities in new indications. Management will host a call to review these updates on June 16 at 8:00 am ET. Please register for the event on the Events and Presentations page of Disc's website ( Bitopertin, DISC-0974, and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide. Summary of Poster Presentations Bitopertin: HELIOS: HELIOS is an ongoing Phase 2, open-label, long-term extension trial that enrolled 86 adult and adolescent patients with EPP from the BEACON and AURORA trials. Patients were randomized to receive 20 mg or 60 mg bitopertin in BEACON and 20 mg or 60 mg bitopertin or placebo in AURORA, with all patients transitioning to a 60 mg daily dose of bitopertin in HELIOS. Longer term treatment with bitopertin was associated with sustained reductions in the disease-causing toxin PPIX, with additional benefit for patients receiving the 60 mg dose continuously Continuous treatment with 60 mg of bitopertin reduced ALT and other exploratory hepatobiliary biomarkers Nearly all participants reported substantial improvements in quality of life measures Bitopertin exhibited a favorable longer-term safety profile with up to 2+ years of exposure and similar safety across adults and adolescents with EPP and XLP DISC-0974: DISC-0974 Phase 1b in MF anemia: Data from the continuation phase of the Phase 1b trial of DISC-0974 in MF anemia as of October 2024 were presented. This multi-center, open-label trial included patients who were: non-transfusion dependent receiving no transfusions (nTD, n=23), transfusion dependent with low transfusion burden (TD Low, n=5) and transfusion dependent with high transfusion burden (TD High, n=7). The trial was comprised of both patients receiving concomitant JAK inhibitor therapy (n=13) and not receiving JAK inhibitor therapy (n=22). DISC-0974 was administered subcutaneously at 14 mg (n=1), 28 mg (n=7), 50 mg (n=12), 75 mg (n=9), or 100 mg (n=6) every 4 weeks for up to 6 treatments. Long-term results demonstrated: Sustained hepcidin suppression, iron mobilization, and reduction in Zinc PPIX, a measure of iron restricted hemoglobin production nTD patients: 50% of evaluable patients achieved major response of sustained mean hemoglobin increase of ≥1.5 g/dL Hematologic improvement was durable through the continuation phase TD Low patients: 80% of evaluable patients achieved major response of transfusion independence over 16 weeks Hematologic improvement was durable, and all major responders remained transfusion independent during the continuation phase TD High patients: 40% of evaluable patients achieved major response of transfusion independence over 12 weeks 1 of 2 patients with a major response entered the continuation phase and remained transfusion independent at Day 225, with follow-up ongoing DISC-0974 was safe and well-tolerated at all evaluated dose levels DISC-0974 in combination with luspatercept and ESA (mouse model): The effect of DISC-0974, luspatercept, and ESA as single agents and DISC-0974 combined with luspatercept or ESA on hematological parameters in wild type mice was evaluated. Results showed: Treatment with DBIO-100 (a mouse analog of DISC-0974) suppressed hepcidin, enhanced iron availability, and boosted erythropoiesis in wild-type mice Combining with DPO (ESA) or RAP-536 (mouse analog of luspatercept) led to additional hematological benefits beyond those agents alone These results demonstrate that DISC-0974 has a distinct mechanism of action among anemia-targeted agents and highlight the potential for synergistic anemia benefits when combining DISC-0974 with other anemia-targeted agents. DISC-3405: Phase 1 Healthy Volunteer Study: Updated SAD/MAD data from the Phase 1 trial of DISC-3405 in healthy volunteers were presented. In the SAD portion of this trial, healthy males and females ages 18 to 65 were given a single dose of placebo (n=10) or DISC-3405 at 75 mg intravenously (IV) (n=6), 37.5 mg subcutaneously (SC) (n=6), 75 mg SC (n=6), 150 mg SC (n=6), or 300 mg SC (n=6). The MAD portion included placebo (n=4), 75 mg SC (n=6), and 150 mg SC (n=6) cohorts dosed every 4 weeks for a total of 2 doses. Consistent with data presented at ASH 2024, results showed: DISC-3405 produced dose-related increases in serum hepcidin with corresponding reductions in serum iron across all dose levels DISC-3405 resulted in deep reductions in serum iron (ranging from 50-80% from baseline) that were sustained and support a once-monthly SC dosing regimen Single and repeat dosing of DISC-3405 demonstrated meaningful reductions in hematologic parameters, including reticulocyte hemoglobin, hemoglobin, and hematocrit DISC-3405 was generally well-tolerated at all evaluated dose levels, with no serious adverse events (AEs), greater than Grade 2 AEs, or AEs leading to study withdrawal These results provide proof of mechanism and support the advancement DISC-3405 into proof of concept studies. Disc has now initiated a Phase 2 trial of DISC-3405 in PV with initial results expected in 2026. Iron Pulse Study: Disc conducted an iron pulse study in healthy volunteers to evaluate the effectiveness of DISC-3405 in inhibiting dietary iron uptake. N=8 healthy volunteers received placebo treatment followed by oral ferrous sulfate tablets on two sequential occasions to establish baseline iron absorption profiles. Participants were then given a single 150mg IV dose of DISC-3405, followed by oral ferrous sulfate 'iron pulses' on the 2nd and 15th days following treatment. DISC-3405 resulted in an average 94% reduction in iron absorption at Day 2 and 68% at Day 15. These results confirm the mechanism of DISC-3405 and demonstrate its ability to block dietary iron absorption, supporting the potential for treating diseases associated with iron overload. About Disc Medicine Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit Disc Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc's expectations with respect to the next stages of its development programs for bitopertin, DISC-0974 and DISC-3405, including projected timelines for the initiation and completion of its clinical trials, anticipated timing of release of data, and other clinical activities; the registrational pathway for bitopertin, including the timing of a potential NDA submission; and the potential of its development programs in new indications. The use of words such as, but not limited to, 'believe,' 'expect,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' 'continue,' 'may,' 'might,' 'plan,' 'will,' 'should,' 'seek,' 'anticipate,' or 'could' or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc's current beliefs, expectations and assumptions regarding the future of Disc's business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc's capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc's product candidates; Disc's plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc's planned preclinical studies and clinical trials; the timing of the availability of data from Disc's clinical trials; Disc's ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc's preclinical studies and clinical trials and the risk that the results of Disc's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of our Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. Media Contact Peg RusconiDeerfield Investor Relations Contact Christina TartagliaPrecision in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Bill banning AI therapy bots in Illinois awaits signature
SPRINGFIELD, Ill. (WCIA) — Illinois could soon require humans to be in charge of all therapy sessions. The Illinois Legislature passed a bill to the governor's desk that would ban the use of therapy offered by Artificial Intelligence. Mental health professionals would also only be able to use AI transcriptions of sessions if the patient consents to it. Illinois bill ending scam gym membership tactic heads to governor's desk The National Association for Social Workers said while artificial intelligence could be a promising tool in the future, right now it is not bound by ethics. 'These AI chat bots, even though you can try to program as best as you can, they're not human,' said Kyle Hillman, the legislative director for NASW-IL. 'They don't have that interaction they don't have that kind of response. And so, they're influenced by what kind of data comes into those products and that influence is changing the biases towards, I think, dangerous conservations.' Durbin pushes to pass DACA bill ahead of 13th anniversary The bill's House sponsor said guardrails need to be set in stone before technology advances too far. 'Our behavioral healthcare system cannot afford to be replaced by unqualified chatbots with no malpractice liability,' Rep. Bob Morgan (D-Deerfield) said in a news release. 'By explicitly laying out what AI technology can and cannot be used for, patients are better protected, providers can continue delivering critical access to care, and treatment plans remain transparent between the client and professional.' If signed into law, Illinois would be the first state to ban these chatbots. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
12 hours ago
- Yahoo
Decatur Memorial Hospital providing sleeping sacks for newborns
DECATUR, Ill. (WCIA) — The state of Illinois is spreading awareness about safe sleeping when it comes to newborns. Sudden Infant Death Syndrome (SIDS) is the leading cause of death in babies under one year old, and now one Macon County hospital wants to help. Decatur Memorial Hospital started giving out sleeping sacks to the parents of a newborn last month. Officials hope this will spread awareness and save more lives. Decatur families excited with new Fairview Park The hospital is taking a new approach when caring for babies and their families. One nurse said it's important as Sudden Infant Death Syndrome, also called SIDS, is starting to rise. 'It is the leading cause of death in infants under one years old,' said nurse manager Danielle Collins. 'And that leads to a variety of different things. It leads to people co-sleeping with their baby, people seeing different things that are not safe on the market for their baby to use.' Collins said to babies, the tight-fitting sleep sacks are comfortable because it symbolizes the womb. In the last few weeks, the hospital has passed out nearly 40 of them. 'This has been in works for well over six-eight months of getting the sleep sacks purchased, the foundation providing them for us,' Collins said. The Illinois Department of Human Services said every three days a baby in Illinois dies in their sleep. The hospital's foundation director, Paul Lidy, said Decatur Memorial has 1,100 sleeping sacks ready to go which will hopefully prevent this problem from getting worse. Illinois Women's Pro Tennis Championship held in Decatur for the first time 'Our goal is to help right from the get-go with a new baby to make sure that they are safely sleeping,' Lidy said. He said the stock is expected to last until 2026, since normally they average between 800-900 births a year. 'We used to give out a baby spoon, something that was sentimental but maybe not as usable,' Lidy said. 'This is a direct way that we can impact that baby by safe swaddling them.' Collins said they're just pushing the initiative to avoid common causes of infant death. 'Myself and my team are here to do every day, day in, day out,' Collins said. 'We want to provide the best quality care we can for our patients; see them not only as a patient, but as a family.' These sleeping sacks are available to every newborn in the hospital. The Illinois Department of Human Services said bed sharing with an infant is up to 10 times higher now. In 2022, there were more than 1,500 deaths related to SIDS. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
